title: Systematic review: the use of proton pump inhibitors and increased susceptibility to enteric infection.
abstract: The use of proton pump inhibitors (PPIs) is increasing worldwide. Suppression of gastric acid alters the susceptibility to enteric bacterial pathogens. AIM  This systematic review was undertaken to examine the relationship between PPI use and susceptibility to enteric infections by a specific pathogen based on published literature and to discuss the potential mechanisms of PPI enhanced pathogenesis of enteric infections. METHODS  PubMed, OVID Medline Databases were searched. Search terms included proton pump inhibitors and mechanisms of, actions of, gastric acid, enteric infections, diarrhoea, Clostridium difficile, Salmonella, Shigella and Campylobacter. RESULTS The use of PPIs increases gastric pH, encourages growth of the gut microflora, increases bacterial translocation and alters various immunomodulatory and anti-inflammatory effects. Enteric pathogens show variable gastric acid pH susceptibility and acid tolerance levels. By multiple mechanisms, PPIs appear to increase susceptibility to the following bacterial enteropathogens: Salmonella, Campylobacter jejuni, invasive strains of Escherichia coli, vegetative cells of Clostridium difficile, Vibrio cholerae and Listeria. We describe the available evidence for enhanced susceptibility to enteric infection caused by Salmonella, Campylobacter and C. difficile by PPI use, with adjusted relative risk ranges of 4.2-8.3 (two studies); 3.5-11.7 (four studies); and 1.2-5.0 (17 of 27 studies) for the three respective organisms. CONCLUSIONS Severe hypochlorhydria generated by PPI use leads to bacterial colonisation and increased susceptibility to enteric bacterial infection. The clinical implication of chronic PPI use among hospitalized patients placed on antibiotics and travellers departing for areas with high incidence of diarrhoea should be considered by their physicians.
authors: University of Texas Health Science Center at Houston School of Public Health, Center for Infectious Diseases, Houston, USA.
authors: C
authors: C
authors: Bavishi
authors: H L
authors: HL
authors: Dupont
mesh_terms: D000897:Anti-Ulcer Agents / Q000009:adverse effects*; D001424:Bacterial Infections / Q000209:etiology*; D004198:Disease Susceptibility; D005744:Gastric Acid / Q000378:metabolism; D005767:Gastrointestinal Diseases / Q000209:etiology*; D006801:Humans; D006863:Hydrogen-Ion Concentration / Q000187:drug effects; D054328:Proton Pump Inhibitors / Q000009:adverse effects*; D012307:Risk Factors; D013997:Time Factors
chemical_list: D000897:Anti-Ulcer Agents; D054328:Proton Pump Inhibitors